U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis Elanco enters the estimated $1.
7 billion global canine dermatology market, highly accretive to existing portfolio In a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet) 1 * Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming days GREENFIELD, Ind.
, Sept. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN ) today announced the U.S.
Food and Drug Administration (FDA) has approved ZenreliaTM, a safe, highly effective, and convenient once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Itching is one of the top reasons pet owners bring their dog to the veterinarian, and pet owners and veterinarians want more canine dermatology options. Approximately 17 million dogs suffer from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity 2 .
Among pet owners who say their dog's itch is not under control, 60% say they've tried treating the itch, but nothing works. 3 The approval of Zenrelia represents an important .